New Medicine Approvals in 2012

New Report Shows Minnesota Clinical Trials Benefit Patients, State Economy and Science

MINNEAPOLIS, MN (December 13, 2013) – Working with Minnesota research institutions, including the members of the Minnesota Clinical Research Alliance (MCRA), the nation's biopharmaceutical research companies have conducted 2,945 clinical trials of new medicines since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).  This total reflects an increase of about 300 trials over the last year.

Research in Minnesota

Research in Vermont

Alabama Clinical Trials Benefit Patients and the Economy

BIRMINGHAM, AL (December 4, 2013) – Working with Alabama research institutions, including several facilities in Birmingham, the nation’s biopharmaceutical research companies have conducted 3,431 clinical trials of new medicines in the state over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Research in Alabama

Nearly 400 Novel Medicines in Development for Infectious Diseases

America’s biopharmaceutical research companies are developing 394 new medicines for infectious diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Infectious diseases were the leading cause of death in the United States until the 1920s

WASHINGTON, D.C. (December 4, 2013) – America’s biopharmaceutical research companies are developing 394 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Infectious Diseases Infographic

Medicines in Development: Infectious Diseases

Pages

Subscribe to RSS - Innovation